These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15915006)

  • 41. The rheological properties of pharmaceutical foam: implications for use.
    Kealy T; Abram A; Hunt B; Buchta R
    Int J Pharm; 2008 May; 355(1-2):67-80. PubMed ID: 18221846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of airway disease on the deposition of inhaled drugs.
    Darquenne C; Corcoran TE; Lavorini F; Sorano A; Usmani OS
    Expert Opin Drug Deliv; 2024 Aug; 21(8):1175-1190. PubMed ID: 39136493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How to engineer aerosol particle properties and biopharmaceutical performance of propellant inhalers.
    Akhuemokhan P; Green NA; Haddrell A; Lewis D; Reid JP; Forbes B
    Int J Pharm; 2023 Mar; 634():122676. PubMed ID: 36738807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis.
    Liu T; Yang D; Liu C
    PLoS One; 2021; 16(9):e0257075. PubMed ID: 34478483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.
    Scichilone N; Benfante A; Morandi L; Bellini F; Papi A
    Patient Relat Outcome Meas; 2014; 5():153-62. PubMed ID: 25473323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in metered dose inhaler technology: formulation development.
    Myrdal PB; Sheth P; Stein SW
    AAPS PharmSciTech; 2014 Apr; 15(2):434-55. PubMed ID: 24452499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors affecting the stability and performance of ipratropium bromide; fenoterol hydrobromide pressurized-metered dose inhalers.
    Ninbovorl J; Sawatdee S; Srichana T
    AAPS PharmSciTech; 2013 Dec; 14(4):1294-302. PubMed ID: 23975571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.
    Scichilone N; Spatafora M; Battaglia S; Arrigo R; Benfante A; Bellia V
    J Asthma Allergy; 2013; 6():11-21. PubMed ID: 23378776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulite: a simple solution to a difficult problem.
    Lewis DA; Ganderton D; Meakin BJ; Brambilla G
    Respiration; 2005; 72 Suppl 1():3-5. PubMed ID: 15915006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.